New Treatment for Hairy Cell Leukemia Granted FDA Approval


Original post, click here

Officials with the FDA have approved AstraZeneca’s moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least 2 prior systemic therapies.